Danone €6.84B Q1 Revenue, Sanofi EPS €1.79, Orange €9.91B Sales Mark Solid First-Quarter Results

Danone reported first-quarter 2025 revenue of €6.84 billion, slightly below estimates of €6.91 billion, with like-for-like sales rising 4.3%, outperforming the expected 3.89%. The company attributed the sales growth to strong consumer demand for its health-focused products, including protein-rich yogurts in North America. Despite some disappointment in volume growth, Danone maintained its full-year guidance, expecting like-for-like sales growth between 3% and 5%. Sanofi posted better-than-expected first-quarter earnings, with business EPS of €1.79 versus estimates of €1.67 and business operating income of €2.90 billion compared to €2.66 billion forecast. The pharmaceutical company benefited from strong demand for its anti-inflammatory drug Dupixent, which generated net product sales of €3.48 billion, slightly above the €3.43 billion estimate. Orange reported a modest 0.6% increase in first-quarter revenue to €9.91 billion, supported by growth in its Middle East and African operations, which helped offset intense price competition in its core French and European markets. The group's EBITDAaL stood at €2.48 billion as of March 31, 2025.